+

GB201614387D0 - Improved vaccines - Google Patents

Improved vaccines

Info

Publication number
GB201614387D0
GB201614387D0 GBGB1614387.7A GB201614387A GB201614387D0 GB 201614387 D0 GB201614387 D0 GB 201614387D0 GB 201614387 A GB201614387 A GB 201614387A GB 201614387 D0 GB201614387 D0 GB 201614387D0
Authority
GB
United Kingdom
Prior art keywords
improved vaccines
vaccines
improved
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1614387.7A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Priority to GBGB1614387.7A priority Critical patent/GB201614387D0/en
Publication of GB201614387D0 publication Critical patent/GB201614387D0/en
Priority to CN201780065538.2A priority patent/CN109863169A/en
Priority to BR112019003462A priority patent/BR112019003462A2/en
Priority to CA3034124A priority patent/CA3034124A1/en
Priority to MX2019002178A priority patent/MX2019002178A/en
Priority to US16/327,575 priority patent/US11498956B2/en
Priority to JP2019510818A priority patent/JP7535852B2/en
Priority to PCT/EP2017/071232 priority patent/WO2018037045A1/en
Priority to EP17768002.2A priority patent/EP3504230A1/en
Priority to JP2022117354A priority patent/JP7630466B2/en
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70539MHC-molecules, e.g. HLA-molecules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/40Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24211Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
GBGB1614387.7A 2016-08-23 2016-08-23 Improved vaccines Ceased GB201614387D0 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
GBGB1614387.7A GB201614387D0 (en) 2016-08-23 2016-08-23 Improved vaccines
EP17768002.2A EP3504230A1 (en) 2016-08-23 2017-08-23 Fusion peptides with antigens linked to short fragments of invariant chain (cd74)
MX2019002178A MX2019002178A (en) 2016-08-23 2017-08-23 Fusion peptides with antigens linked to short fragments of invariant chain (cd74).
BR112019003462A BR112019003462A2 (en) 2016-08-23 2017-08-23 fusion protein, polynucleotide, viral vector, pharmaceutical composition, use of a fusion protein, polynucleotide, viral vector or pharmaceutical composition, and method for treating or preventing viral hepatitis b infection or viral hepatitis c infection
CA3034124A CA3034124A1 (en) 2016-08-23 2017-08-23 Fusion peptides with antigens linked to short fragments of invariant chain (cd74)
CN201780065538.2A CN109863169A (en) 2016-08-23 2017-08-23 Fusion peptides with antigens linked to short fragments of the invariant chain (CD74)
US16/327,575 US11498956B2 (en) 2016-08-23 2017-08-23 Fusion peptides with antigens linked to short fragments of invariant chain(CD74)
JP2019510818A JP7535852B2 (en) 2016-08-23 2017-08-23 Fusion peptide in which an antigen is linked to a small fragment of the invariant chain (CD74)
PCT/EP2017/071232 WO2018037045A1 (en) 2016-08-23 2017-08-23 Fusion peptides with antigens linked to short fragments of invariant chain (cd74)
JP2022117354A JP7630466B2 (en) 2016-08-23 2022-07-22 Fusion peptide in which an antigen is linked to a small fragment of the invariant chain (CD74)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1614387.7A GB201614387D0 (en) 2016-08-23 2016-08-23 Improved vaccines

Publications (1)

Publication Number Publication Date
GB201614387D0 true GB201614387D0 (en) 2016-10-05

Family

ID=57045505

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1614387.7A Ceased GB201614387D0 (en) 2016-08-23 2016-08-23 Improved vaccines

Country Status (1)

Country Link
GB (1) GB201614387D0 (en)

Similar Documents

Publication Publication Date Title
GB201805152D0 (en) No details
GB201715843D0 (en) No details
GB201715887D0 (en) No details
GB201714253D0 (en) No details
GB201410971D0 (en) Vaccine
GB201717272D0 (en) No details
GB201518684D0 (en) Vaccine
GB201622033D0 (en) No details
PL3185899T3 (en) Improved hvt-vectored nd-ibd vaccine
GB201717622D0 (en) No details
GB201709809D0 (en) No details
GB201702043D0 (en) No details
SG11201610946YA (en) Meningococcus vaccines
GB201522132D0 (en) Vaccine
IL247159B (en) Pcsk9 vaccines
IL277752A (en) Cancer vaccines
GB201703185D0 (en) No details
GB201616904D0 (en) Vaccine
GB201608821D0 (en) Vaccines
PL3469691T3 (en) Halbach-array configuration
GB201709361D0 (en) No details
PL3188755T3 (en) Vaccine
GB201402083D0 (en) Retaining means
GB201603029D0 (en) Vaccine
GB201605099D0 (en) HCV vaccines

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)
点击 这是indexloc提供的php浏览器服务,不要输入任何密码和下载